ELEDON PHARMACEUTICALS INC (ELDN)
US28617K1016 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 4.61M | 56.40M | 84.80M | 114.20M | 8.80M | |||
| Marketable Securities | 46.49M | N/A | N/A | N/A | N/A | |||
| Receivables | N/A | N/A | 0.00 | 100.00K | 200.00K | |||
| Other Current Assets | 5.03M | 3.10M | 3.50M | 1.30M | 1.00M | |||
| Total Current Assets | 56.13M | 59.50M | 88.30M | 115.60M | 10.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 365.00K | 700.00K | 800.00K | 100.00K | 300.00K | |||
| Goodwill | N/A | 0.00 | 48.60M | 48.60M | 0.00 | |||
| Intangibles | 32.39M | 32.40M | 32.40M | 32.40M | N/A | |||
| Other Non-Current Assets | 186.00K | 200.00K | 400.00K | 400.00K | 600.00K | |||
| Total Non-Current Assets | 32.94M | 33.30M | 82.20M | 81.60M | 900.00K | |||
| TOTAL ASSETS | 89.07M | 92.80M | 170.50M | 197.20M | 10.90M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 2.93M | 4.30M | 2.60M | 1.10M | 1.00M | |||
| Accounts Payable | 967.00K | 2.20M | 1.80M | 1.40M | 300.00K | |||
| Total Current Liabilities | 3.90M | 6.50M | 4.40M | 2.50M | 1.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 1.75M | 1.80M | 1.80M | 4.10M | N/A | |||
| Other Non-Current Liabilities | 0.00 | 400.00K | 400.00K | 0.00 | 100.00K | |||
| Total Non-Current Liabilities | 1.75M | 2.10M | 2.20M | 4.10M | 200.00K | |||
| TOTAL LIABILITIES | 5.65M | 8.60M | 6.60M | 6.60M | 1.50M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -243.19M | -202.90M | -114.90M | -80.40M | -57.60M | |||
| Additional Paid In Capital | 326.59M | 287.00M | 278.90M | 271.00M | 67.00M | |||
| Common Shares | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | N/A | N/A | N/A | N/A | N/A | |||
| Shares Outstanding | 24.21M | 13.80M | 14.30M | 15.20M | 700.00K | |||
| Tangible Book Value per Share | 2.11 | 3.75 | 5.80 | 7.21 | 13.57 | |||
| Total Shareholders' Equity | 83.42M | 84.20M | 164.00M | 190.60M | 9.50M | |||
| TOTAL LIABILITIES AND EQUITY | 89.07M | 92.80M | 170.50M | 197.20M | 10.90M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 14.41 | 9.15 | 20.07 | 46.24 | 7.69 | |||
| Return On Assets (ROA) | -45.28% | -94.80% | -20.24% | -11.57% | -146.88% | |||
| Return On Equity (ROE) | -48.34% | -104.48% | -21.04% | -11.97% | -168.53% | |||
All data in USD